Atossa Therapeutics (ATOS) announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback